» Articles » PMID: 18825681

Expanded Criteria for Liver Transplantation in Patients with Cirrhosis and Hepatocellular Carcinoma

Overview
Journal Liver Transpl
Date 2008 Oct 1
PMID 18825681
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community. The main aim of this study was to evaluate the survival rates and recurrence probabilities of a new proposal for criteria (up to 3 tumors, each no larger than 5 cm, and a cumulative tumor burden </= 10 cm). Patients with cirrhosis and HCC included on the waiting list (WL) from 1991 to 2006 were retrospectively analyzed. Outcomes in patients who had tumors within and beyond the MC were compared. The survival analysis was done (1) with the intention-to-treat principle and (2) among transplanted patients. A total of 281 patients were included in WL. Twenty-four cases did not undergo OLT (a dropout rate of 8.5%); all but 1 case had tumors within the MC. Of the 257 transplanted patients, 26 had tumors beyond the MC in the pre-OLT evaluation. Based on the intention-to-treat analysis, the 5-year survival was 56% versus 66% in patients who had tumors within and beyond the MC, respectively (P = 0.487). Among transplanted patients, the 5-year survival was 62% versus 69%, respectively (P = 0.734). Through multivariate analysis, microvascular invasion was an independent prognostic factor of poor survival (P = 0.004). The recurrence probabilities at 1 and 5 years were 7% versus 12% and 14% versus 28% in patients with tumors within and beyond the MC, respectively (P = 0.063). The multivariate analysis demonstrated that both poorly differentiated tumors (P < 0.001) and microvascular invasion (P < 0.001) increased the risk of recurrence. The expansion to up to 3 nodules, each up to 5 cm, and a cumulative tumor burden </= 10 cm did not result in a reduction of survival in comparison with patients who had tumors within the MC.

Citing Articles

Hepatocellular carcinoma recurrence: Predictors and management.

Abdelhamed W, El-Kassas M Liver Res. 2025; 7(4):321-332.

PMID: 39958776 PMC: 11791921. DOI: 10.1016/j.livres.2023.11.004.


Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?.

Karabulut E, Akbulut S, Samdanci E, Akatli A, Elsarawy A, Kucukakcali Z J Clin Med. 2025; 14(1.

PMID: 39797227 PMC: 11720816. DOI: 10.3390/jcm14010144.


Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?.

Badwei N World J Transplant. 2024; 14(3):96637.

PMID: 39295978 PMC: 11317853. DOI: 10.5500/wjt.v14.i3.96637.


Transplant Oncology: An Emerging Discipline of Cancer Treatment.

Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S Cancers (Basel). 2023; 15(22).

PMID: 38001597 PMC: 10670243. DOI: 10.3390/cancers15225337.


Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria.

Beumer B, van Vugt J, Sapisochin G, Yoon P, Bongini M, Lu D J Cachexia Sarcopenia Muscle. 2023; 13(5):2373-2382.

PMID: 36622940 PMC: 9530497. DOI: 10.1002/jcsm.13053.